Nonerythropoietic properties of erythropoietin: Implication for tissue protection

Journal of Investigative Medicine

Volumn 59, Issue 7, 2011, Pages 1083-1085

  Rathod, Dhanesh B ^a   Salahudeen, Abdulla K ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cell injury; Erythropoietin; Tissue protection

Indexed keywords

CISPLATIN; CREATININE; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; HEMOGLOBIN; JANUS KINASE; JANUS KINASE INHIBITOR; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PLACEBO; PROTEIN KINASE B; RECOMBINANT ERYTHROPOIETIN; STAT5 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CELL DAMAGE; CONFERENCE PAPER; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; ENZYME PHOSPHORYLATION; HEMOGLOBIN DETERMINATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INJURY; INTENSIVE CARE UNIT; KIDNEY INJURY; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE CELL; NEPHROTOXICITY; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); RAT; SIGNAL TRANSDUCTION; THROMBOEMBOLISM; THROMBOSIS; TISSUE INJURY;

EID: 84856699747     PISSN: 17088267     EISSN: 17088267     Source Type: Journal    
DOI: 10.2310/JIM.0b013e31822cf86e     Document Type: Conference Paper

References (21)

1. Siren AL, Fratelli M, Brines M, et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci USA. 2001;98:4044-4049. (Pubitemid 32249895)
2. Junk AK, Mammis A, Savitz SI, et al. Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. Proc Natl Acad Sci USA. 2002;99:10659-10664.
3. Yang CW, Li C, Jung JY, et al. Preconditioning with erythropoietin protects against subsequent ischemia-reperfusion injury in rat kidney. FASEB J. 2003;17:1754-1755.
4. Calvillo L, Latini R, Kajstura J, et al. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA. 2003;100:4802-4806. (Pubitemid 36457809)
5. Erbayraktar S, Grasso G, Sfacteria A, et al. Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc Natl Acad Sci USA. 2003;100:6741-6746. (Pubitemid 36666650)
6. Vesey DA, Cheung C, Pat B, et al. Erythropoietin protects against ischaemic acute renal injury. Nephrol Dial Transplant. 2004; 19:348-355. (Pubitemid 38195983)
7. Vaziri ND, Zhou XJ, Liao SY. Erythropoietin enhances recovery from cisplatin-induced acute renal failure. Am J Physiol. 1994; 266:F360-F366.
8. Salahudeen AK, Haider N, Jenkins J, et al. Antiapoptotic properties of erythropoiesis-stimulating proteins in models of cisplatin-induced acute kidney injury. Am J Physiol Renal Physiol. 2008;294: F1354-F1365.
9. Salahudeen A, Poovala V, Parry W, et al. Cisplatin induces N-acetyl cysteine suppressible F2-isoprostane production and injury in renal tubular epithelial cells. J Am Soc Nephrol. 1998;9:1448-1455. (Pubitemid 28354555)
10. Bittorf T, Seiler J, Ludtke B, et al. Activation of STAT5 during EPO-directed suppression of apoptosis. Cell Signal. 2000;12: 23-30. (Pubitemid 30017965)
11. Bao H, Jacobs-Helber SM, Lawson AE, et al. Protein kinase B (c-Akt), phosphatidylinositol 3-kinase, and STAT5 are activated by erythropoietin (EPO) in HCD57 erythroid cells but are constitutively active in an EPO-independent, apoptosis-resistant subclone (HCD57-SREI cells). Blood. 1999;93:3757-3773. (Pubitemid 29249822)
12. Corwin HL, Gettinger A, Fabian TC, et al. Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med. 2007;357:965-976. (Pubitemid 47367076)
13. Coleman T, Brines M. Recombinant human erythropoietin in critical illness: a role beyond anemia? Crit Care. 2004;8:337-341. (Pubitemid 39468054)
14. Maiese K, Li F, Chong ZZ. New avenues of exploration for erythropoietin. JAMA. 2005;293:90-95. (Pubitemid 40066704)
15. Jubinsky PT, Krijanovski OI, Nathan DG, et al. The beta chain of the interleukin-3 receptor functionally associates with the erythropoietin receptor. Blood. 1997;90(5):1867-1873. (Pubitemid 27377296)
16. Hand CC, Brines M. Promises and pitfalls in erythropoietin-mediated tissue protection: are nonerythropoietic derivatives a way forward? J Investig Med. 2011;59:1073-1082.
17. Wojchowski DM, Gregory RC, Miller CP, et al. Signal transduction in the erythropoietin receptor system. Exp Cell Res. 199;253(1):143-156.
18. Agell N, Bachs O, Rocamora N, et al. Modulation of the Ras/Raf/MEK/ERK pathway by Ca(2+), and calmodulin. Cell Signal. 2002;14(8):649-654. (Pubitemid 34518618)
19. Brines M, Cerami A. Discovering erythropoietin's extra-hematopoietic functions: biology and clinical promise. Kidney Int. 2006;70:246-250. (Pubitemid 44086573)
20. Brines M. The therapeutic potential of erythropoiesis-stimulating agents for tissue protection: a tale of two receptors. Blood Purif. 2010;29:86-92.
21. Brines M, Patel NS, Villa P, et al. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci USA. 2008;105:10925-10930.